Get notified when RGEN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Material Weakness (worsened) — Disclosure controls remain ineffective due to material weaknesses in IT general controls and business process-level controls, with remediation ongoing.
NASDAQ: RGEN REPLIGEN CORP 10-Q

revenue $204.1M, net income $5.0M. Repligen to acquire BioLife; Q2 net income falls 66% on tax and divestiture charges

Filed July 29, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~1 min read

Key Changes

  • high

    Agreed to acquire BioLife Solutions for ~$1.5B (64% stock, 36% cash), expected to close in Q4 2026; adds cell processing tools for cell and gene therapy.

    Subsequent Events verify on EDGAR →
  • high

    Net income fell 66.3% to $5.0M despite operating income rising, driven by a $9.9M below-the-line swing (non-operating/other -$4.1M, income tax -$5.8M).

    MD&A: Results verify on EDGAR →
  • high

    Sold Polymem for $3.6M, recognizing a $13.7M loss; effective tax rate for Q2 jumped to 64.6% from 18.4%.

    MD&A: Divestiture verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.

Partner

Trade RGEN commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 7, 2026 · How we verify